NCT06397131View on ClinicalTrials.gov

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 6, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

July 24, 2026

Conditions
Macular Telangiectasia Type 2
Interventions
COMBINATION_PRODUCT

NT-501 CNTF Implant

Single implantation of CNTF-secreting NT-501 hCNTF device into one eye.

Trial Locations (3)

49546

Foundation for Vision Research, Grand Rapids

77401

Retina Consultants of Texas, Bellaire

94598

Bay Area Retina Associates, A Medical Group, Walnut Creek

Sponsors
All Listed Sponsors
lead

Neurotech Pharmaceuticals

INDUSTRY